Medpace Holdings, Inc. (MEDP)

$376.49

-4.01

(-1.05%)▲

Live

Performance

  • $374.33
    $385.70
    $376.49
    downward going graph

    0.57%

    Downside

    Day's Volatility :2.95%

    Upside

    2.39%

    downward going graph
  • $227.21
    $459.77
    $376.49
    downward going graph

    39.65%

    Downside

    52 Weeks Volatility :50.58%

    Upside

    18.11%

    downward going graph

Returns

PeriodMedpace Holdings, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-3.9%
6.5%
0.0%
6 Months
27.62%
7.1%
0.0%
1 Year
48.33%
9.8%
0.0%
3 Years
109.72%
14.2%
-20.2%

Highlights

Market Capitalization
11.6B
Book Value
$24.69
Earnings Per Share (EPS)
10.63
PE Ratio
35.27
PEG Ratio
2.68
Wall Street Target Price
416.91
Profit Margin
16.74%
Operating Margin TTM
19.91%
Return On Assets TTM
14.33%
Return On Equity TTM
58.86%
Revenue TTM
2.0B
Revenue Per Share TTM
65.92
Quarterly Revenue Growth YOY
14.6%
Gross Profit TTM
925.1M
EBITDA
409.5M
Diluted Eps TTM
10.63
Quarterly Earnings Growth YOY
0.43
EPS Estimate Current Year
11.55
EPS Estimate Next Year
13.02
EPS Estimate Current Quarter
2.54
EPS Estimate Next Quarter
2.71

Analyst Recommendation

Buy
    83%Buy
    16%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Medpace Holdings, Inc.(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
9
8
Hold
2
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 10.74%

Current $376.49
Target $416.91

Company Financials

FY18Y/Y Change
Revenue
704.6M
↑ 61.55%
Net Income
73.2M
↑ 87.07%
Net Profit Margin
10.39%
↑ 1.42%
FY19Y/Y Change
Revenue
861.0M
↑ 22.19%
Net Income
100.4M
↑ 37.25%
Net Profit Margin
11.67%
↑ 1.28%
FY20Y/Y Change
Revenue
925.9M
↑ 7.54%
Net Income
145.4M
↑ 44.74%
Net Profit Margin
15.7%
↑ 4.03%
FY21Y/Y Change
Revenue
1.1B
↑ 23.38%
Net Income
181.8M
↑ 25.08%
Net Profit Margin
15.92%
↑ 0.22%
FY22Y/Y Change
Revenue
1.5B
↑ 27.8%
Net Income
245.4M
↑ 34.93%
Net Profit Margin
16.81%
↑ 0.89%
FY23Y/Y Change
Revenue
1.9B
↑ 29.17%
Net Income
282.8M
↑ 15.26%
Net Profit Margin
15.0%
↓ 1.81%
Q1 FY23Q/Q Change
Revenue
434.1M
↑ 10.14%
Net Income
72.9M
↑ 6.15%
Net Profit Margin
16.79%
↓ 0.63%
Q2 FY23Q/Q Change
Revenue
460.9M
↑ 6.17%
Net Income
61.1M
↓ 16.22%
Net Profit Margin
13.25%
↓ 3.54%
Q3 FY23Q/Q Change
Revenue
492.5M
↑ 6.86%
Net Income
70.6M
↑ 15.53%
Net Profit Margin
14.32%
↑ 1.07%
Q4 FY23Q/Q Change
Revenue
498.4M
↑ 1.2%
Net Income
78.3M
↑ 10.98%
Net Profit Margin
15.71%
↑ 1.39%
Q1 FY24Q/Q Change
Revenue
511.0M
↑ 2.54%
Net Income
102.6M
↑ 31.03%
Net Profit Margin
20.07%
↑ 4.36%
Q2 FY24Q/Q Change
Revenue
528.1M
↑ 3.34%
Net Income
88.4M
↓ 13.88%
Net Profit Margin
16.73%
↓ 3.34%
FY18Y/Y Change
Total Assets
967.9M
↑ 1.81%
Total Liabilities
378.2M
↓ 15.42%
FY19Y/Y Change
Total Assets
1.1B
↑ 18.09%
Total Liabilities
416.8M
↑ 10.19%
FY20Y/Y Change
Total Assets
1.4B
↑ 21.66%
Total Liabilities
584.9M
↑ 40.33%
FY21Y/Y Change
Total Assets
1.7B
↑ 19.36%
Total Liabilities
707.0M
↑ 20.88%
FY22Y/Y Change
Total Assets
1.4B
↓ 18.52%
Total Liabilities
966.1M
↑ 36.65%
FY23Y/Y Change
Total Assets
1.7B
↑ 22.5%
Total Liabilities
1.1B
↑ 13.64%
Q1 FY23Q/Q Change
Total Assets
1.4B
↑ 3.2%
Total Liabilities
1.0B
↑ 8.52%
Q2 FY23Q/Q Change
Total Assets
1.4B
↑ 0.8%
Total Liabilities
1.0B
↓ 3.11%
Q3 FY23Q/Q Change
Total Assets
1.5B
↑ 5.67%
Total Liabilities
1.0B
↓ 0.01%
Q4 FY23Q/Q Change
Total Assets
1.7B
↑ 11.44%
Total Liabilities
1.1B
↑ 8.08%
Q1 FY24Q/Q Change
Total Assets
1.8B
↑ 8.39%
Total Liabilities
1.1B
↑ 2.4%
Q2 FY24Q/Q Change
Total Assets
1.9B
↑ 6.92%
Total Liabilities
1.2B
↑ 2.86%
FY18Y/Y Change
Operating Cash Flow
156.6M
↑ 60.79%
Investing Cash Flow
-17.0M
↑ 38.7%
Financing Cash Flow
-141.6M
↑ 44.72%
FY19Y/Y Change
Operating Cash Flow
201.9M
↑ 28.92%
Investing Cash Flow
-19.1M
↑ 12.79%
Financing Cash Flow
-73.9M
↓ 47.79%
FY20Y/Y Change
Operating Cash Flow
258.7M
↑ 28.14%
Investing Cash Flow
-31.2M
↑ 63.05%
Financing Cash Flow
-82.3M
↑ 11.32%
FY21Y/Y Change
Operating Cash Flow
263.3M
↑ 1.8%
Investing Cash Flow
-31.4M
↑ 0.48%
Financing Cash Flow
-44.5M
↓ 45.97%
FY22Y/Y Change
Operating Cash Flow
388.1M
↑ 47.36%
Investing Cash Flow
-38.7M
↑ 23.52%
Financing Cash Flow
-775.8M
↑ 1645.16%
Q1 FY23Q/Q Change
Operating Cash Flow
80.1M
↓ 41.42%
Investing Cash Flow
-9.5M
↑ 3.07%
Financing Cash Flow
-52.7M
↓ 59.82%
Q2 FY23Q/Q Change
Operating Cash Flow
82.5M
↑ 3.05%
Investing Cash Flow
-8.5M
↓ 10.9%
Financing Cash Flow
-82.2M
↑ 56.05%
Q3 FY23Q/Q Change
Operating Cash Flow
114.4M
↑ 38.62%
Investing Cash Flow
-8.7M
↑ 2.3%
Financing Cash Flow
-49.3M
↓ 40.07%

Technicals Summary

Sell

Neutral

Buy

Medpace Holdings, Inc. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Medpace Holdings, Inc.
Medpace Holdings, Inc.
-6.13%
27.62%
48.33%
109.72%
496.77%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-3.67%
-10.34%
-15.37%
-31.35%
65.77%
Agilent Technologies Inc.
Agilent Technologies Inc.
1.42%
3.05%
5.07%
-10.16%
94.22%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
6.51%
8.62%
3.5%
12.36%
106.99%
Danaher Corp.
Danaher Corp.
6.51%
15.92%
1.97%
-6.92%
89.83%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
10.0%
7.5%
0.14%
-6.07%
45.29%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Medpace Holdings, Inc.
Medpace Holdings, Inc.
35.27
35.27
2.68
11.55
0.59
0.14
NA
24.69
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
45.67
45.67
4.75
11.06
0.72
0.23
NA
18.93
Agilent Technologies Inc.
Agilent Technologies Inc.
31.63
31.63
2.7
5.2
0.21
0.08
0.01
21.31
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
35.72
35.72
2.81
21.71
0.14
0.05
0.0
120.87
Danaher Corp.
Danaher Corp.
48.76
48.76
3.13
6.99
0.08
0.04
0.0
68.92
Iqvia Holdings Inc.
Iqvia Holdings Inc.
30.13
30.13
1.33
11.19
0.23
0.05
NA
36.83
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Medpace Holdings, Inc.
Medpace Holdings, Inc.
Buy
$11.6B
496.77%
35.27
16.74%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$38.8B
65.77%
45.67
23.26%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$38.9B
94.22%
31.63
18.84%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$219.4B
106.99%
35.72
14.2%
Danaher Corp.
Danaher Corp.
Buy
$191.9B
89.83%
48.76
17.83%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$42.3B
45.29%
30.13
9.39%

Insights on Medpace Holdings, Inc.

  • Increasing Revenue

    Revenue is up for the last 17 quarters, 204.99M → 528.10M (in $), with an average increase of 5.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 102.59M → 88.35M (in $), with an average decrease of 13.9% per quarter

Institutional Holdings

  • Vanguard Group Inc

    8.08%

  • BlackRock Inc

    8.05%

  • Wasatch Advisors LP

    3.15%

  • Amvescap Plc.

    2.63%

  • State Street Corporation

    2.25%

  • TD Asset Management Inc

    1.85%

Company Information

a therapeutically focused leader in research-based drug development, medpace builds strong strategic partnerships with select sponsors to advance the most efficient and cost-effective path to drug approval. as a full service, global clinical research organization (cro), medpace sees itself as a steward of your drug, leveraging its extensive medical and regulatory expertise to deliver additional input, strategy, and efficiencies to each and every phase of the clinical trial. from custom solutions addressing the needs of small and midsize biotechnology companies to full-service offerings for global pharmaceutical companies, medpace has the breadth, depth, and flexibility to deliver a superior result, specific to your needs, on six continents.

Organization
Medpace Holdings, Inc.
Employees
5800
CEO
Dr. August James Troendle M.D.
Industry
Commercial Services

Discover More

FAQs